o
|
Preliminary Proxy Statement
|
o
|
Confidential, for Use of the Commission only (as permitted by Rule 14a-6(e)(2))
|
o
|
Definitive Proxy Statement
|
o
|
Definitive Additional Materials
|
x
|
Soliciting Material Pursuant to Rule 14a-12
|
x
|
No fee required.
|
|
o
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
|
(1)
|
Title of each class of securities to which transaction applies:
|
|
(2)
|
Aggregate number of securities to which transaction applies:
|
|
(3)
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|
|
(4)
|
Proposed maximum aggregate value of transaction:
|
|
(5)
|
Total fee paid:
|
|
o
|
Fee paid previously with preliminary materials.
|
|
o
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule
|
and the date of its filing. | ||
(1)
|
Amount Previously Paid:
|
|
(2)
|
Form, Schedule or Registration Statement No.:
|
|
(3)
|
Filing Party:
|
|
(4)
|
Date Filed:
|
|
Strengthening Roche Diagnostics' offering in life sciences research and diagnostics Illumina Acquisition: Conference call with media, analysts and investors 25 Jan 2012 |
This presentation contains certain forward -looking statements. These forward -looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward -looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website -- www.roche.com All mentioned trademarks are legally protected 2 |
THIS PRESENTATION IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL ILLUMINA COMMON STOCK. THE SOLICITATION AND OFFER TO BUY ILLUMINA COMMON STOCK WILL ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. THE OFFER TO PURCHASE AND RELATED MATERIALS WILL BE FILED BY ROCHE WITH THE SECURITIES AND EXCHANGE COMMISSION (SEC), AND INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ROCHE WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW. SEC.GOV. THE OFFER TO PURCHASE AND RELATED MATERIALS MAY ALSO BE OBTAINED (WHEN AVAILABLE) FOR FREE BY CONTACTING THE INFORMATION AGENT FOR THE TENDER OFFER, MACKENZIE PARTNERS, AT (212) 929-5500 OR (800) 322-2885 (TOLL-FREE). ROCHE WILL BE FILING A PROXY STATEMENT ON SCHEDULE 14A AND OTHER RELEVANT DOCUMENTS WITH THE SEC IN CONNECTION WITH ITS SOLICITATION OF PROXIES FOR THE 2012 ANNUAL MEETING OF ILLUMINA (THE "PROXY STATEMENT") . PROMPTLY AFTER FILING A DEFINITIVE PROXY STATEMENT WITH THE SEC, ROCHE WILL MAIL THE PROXY STATEMENT AND A PROXY CARD TO EACH ILLUMINA STOCKHOLDER ENTITLED TO VOTE AT THE 2012 ANNUAL MEETING. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT CAREFULLY AND IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. INVESTORS AND SECURITY HOLDERS MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS FILED BY ROCHE WITH THE SEC AT THE WEBSITE MAINTAINED BY THE SEC AT WWW. SEC.GOV. THE PROXY STATEMENT AND RELATED MATERIALS MAY ALSO BE OBTAINED (WHEN AVAILABLE) FOR FREE BY CONTACTING THE INFORMATION AGENT FOR THE TENDER OFFER, MACKENZIE PARTNERS, AT (212) 929-5500 OR (800) 322-2885 (TOLL-FREE). ROCHE HOLDING LTD, CKH ACQUISITION CORPORATION AND THE INDIVIDUALS NOMINATED BY CKH ACQUISITION CORPORATION FOR ELECTION TO ILLUMINA'S BOARD OF DIRECTORS (THE "ROCHE NOMINEES") MAY BE DEEMED TO BE PARTICIPANTS IN THE SOLICITATION OF PROXIES FROM ILLUMINA STOCKHOLDERS FOR USE AT THE 2012 ANNUAL MEETING OF STOCKHOLDERS, OR AT ANY ADJOURNMENT OR POSTPONEMENT THEREOF. THE DIRECTORS AND EXECUTIVE OFFICERS OF ROCHE HOLDING LTD AND CKH ACQUISITION CORPORATION WHO MAY BE PARTICIPANTS IN THE SOLICITATION OF PROXIES HAVE NOT BEEN DETERMINED AS OF THE DATE OF THIS PRESENTATION. NO ADDITIONAL COMPENSATION WILL BE PAID TO SUCH DIRECTORS AND EXECUTIVE OFFICERS FOR SUCH SERVICES. INVESTORS AND SECURITY HOLDERS CAN OBTAIN ADDITIONAL INFORMATION REGARDING THE DIRECT AND INDIRECT INTERESTS OF THE ROCHE NOMINEES AND OTHER PARTICIPANTS BY READING THE DEFINITIVE PROXY STATEMENT WHEN IT BECOMES AVAILABLE. 3 |
Strategic Rationale Transforming acquisitions have strengthened the Diagnostics business *Immunohistochemistry / In situ hybridisation ** Electrochemiluminescence ***Polymerase Chain Reaction 1991 2003 2007 2012 Access to leading Sequencing technology Access to leading IHC/ISH* technology Access to leading ECL** technology Access to leading PCR*** technology Technologies Market position PCR*** Immunoassays Clinical Chemistry IHC/ISH* Sequencing # 1 Molecular Testing # 1 Serum Work Area # 1 Tissue Testing # 1 Sequencing 4 |
Roche Diagnostics Overview Illumina Overview Acquisition Rationale Transaction Financials 5 |
Roche Diagnostics: Leading business in IVD Number 1 in in-vitro diagnostics* (IVD) Growing above the market** Broad array of technologies Chemistry and ELISA Arrays Sequencing IHC/ ISH PCR Cellular analysis Active in over 130 countries Commercial Reach Direct Roche Presence Distributors Source: Industry Analyst Reports, Company reports * Based on 2010 data ** Sept YTD 2011 growth (LC) 6 |
Roche Diagnostics: Broad portfolio Spanning Life Sciences, Lab Diagnostics and Patient self-monitoring 8% of sales 64% of sales 28% of sales % Divisional sales 2010 Life Science App. Science Academia and Pharma In Vitro Diagnostics (IVD) Molecular Dx Molecular lab Blood screen. Tissue Dx Pathology lab Professional Dx Central lab ER / ICU Doc. office Diabetes Care Diabetes Patient 7 |
Roche Diagnostics: Applied Science business Provides access to basic science, potential new biomarkers and emerging technologies Life Science App. Science Academia and Pharma PCR Arrays Sequencing Cellular [] Access to leading scientific institutions and biotech companies [] Active participation in cutting-edge research [] Gain first-hand experience to pioneer transition of new tools into clinical diagnostics 8 |
Roche Diagnostics Overview Illumina Overview Acquisition Rationale Transaction Financials 9 |
Illumina: Company overview Solid business with strong revenue and margins Company Facts []Founded in 1998 []Based in San Diego, California []~2,100 FTEs (year-end 2010) 2010 Financials []Revenue '10: USD 903 m []CAGR '06--'10: 49% []Operating Margin: 23% Source: Analyst reports, Thomson Financials, Company website * not complete product range Product Portfolio* Sequencing Microarrays HiSeq 2000 MiSeq GA IIx HiSeq 1000 HiScan SQ HiScan iScan Bead Xpress 2010 Business Mix Segment Mix 7% 35% 6% 22% 30% Sequencing Instruments Service Sequencing Consumables Arrays Instruments Arrays Consumables Customer Mix 10% 10% 80% Academic and Gov't Clinical Pharma/Biotech Applied/Industry Geographic Mix 20% 25% 55% U. S. ROW Europe 10 |
Roche Diagnostics Overview Illumina Overview Acquisition Rationale Transaction Financials 11 < |
Acquisition Rationale Increase market participation Strengthen portfolio Unlock commercial potential Entry into IVD 12 < |
Rationale: Increase market participation Strengthens presence in fast-growing market Sequencing Market Projected sales, m USD 200 201 2015 5 0 E Source: Analysts reports, Roche analysis Key Growth Drivers [] Increasing ease of use, throughput, speed and affordability [] Biomarker discovery opportunities [] Adoption into clinical and routine diagnostics (e. g. oncology, virology) Market Challenges [] Research funding environment [] Rapidly evolving technologies [] Transition to IVD Next Generation Sequencing Sanger Sequencing 700 1,200 2,100 +12% 13 |
Rationale: Strengthen portfolio Complements Roche's offering in sequencing 'Short Read' Applications Whole genome Re-sequencing RNA-seq Epigenomics ------------- 'Long Read' Applications Amplicon De-Novo Illumina Roche High throughput Low throughput Illumina Roche GS FLX MiSeq GS Junior Source: Roche analysis 14 |
Rationale: Strengthen portfolio Broadens menu of technologies for diagnostics customers Genomics (DNA/RNA) Sequencing Microarrays PCR SR LR HT LT Discovery Routine IVD In development BeadXpress cobas 4800 Benchmark cobas e modules cobas c modules Tissue IHC/ISH Proteomics Immunoassay Metabolics Chemistry SR = short reads; LR = long reads; HT = high throughput; LT = low throughput Source: Company website 15 |
Rationale: Unlock commercial potential Leveraging each company's strengths Illumina Sales 2010 USD 903 m U. S. Source: Company reports, Analysts reports 45% 55% Ex U.S. Roche Sales 2010 CHF 10,415 m Ex US 77% 23% U. S [] Focused on large academic facilities [] Solid relationships with genome centers [] Strong presence in U.S. [] Large installed base in hospital and universities [] Established infrastructure in clinical diagnostics [] Global commercial presence 16 < |
Rationale: Entry into IVD market Utilise Roche's comprehensive diagnostics expertise to accelerate transition of sequencing into routine clinical use Sequencing as Sequencing as research tool routine IVD test Development research IVD system and Technical and clinical Regulatory approval Scale, global reach, systems and reagents assay development validation and reimbursement established diagnostic network 17 |
Rationale: Entry into IVD market Leverage unique Roche Rx-Dx collaboration to develop IVD companion diagnostics tests Pharmaceuticals Research Development Commercialisation Unrestricted know-how More efficient Faster adoption of PHC solutions and IP exchange development (medicine and test) Technically validated IVD Clinically validated Research assay assay IVD assay Diagnostics 18 |
Rationale: Summary Increase Strengthen our participation in fast-growing and increasingly market important sequencing market participation Strengthen Strengthens Roche's portfolio in sequencing and microarrays portfolio and complements offering in genomics research and diagnostics Unlock Capitalise on the combined capabilities and customer commercial potential network of both companies to fully realise the potential of the business Leverage Roche's diagnostics expertise and global reach to Entry into IVD drive biomarker discovery and transition of sequencing into clinical and routine diagnostics 19 |
Roche Diagnostics Overview Illumina Overview Acquisition Rationale Transaction Financials 20 |
Transaction Financials: Staying focused Aim to lead in selected business/disease areas (Oncolog) y(I)n A(f)l u a(t) m(o) m(im) am(ti)o(u) n n / e M d a(i) c(s) u e l a a s(r) /(e) R(seti)n B a i l(ologi)c D s(iagnostic) s (Sequencin) g -------- ----------------------------------------------------------------------------------------------------------------------------------- ----------------- Roche 1 7 2* 1 1 1 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Novartis 2 5 1* -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Abbott 1 4 2 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Sanofi 4 6 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Pfizer 6 2 7 8 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Merck 10 8 3 9 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- JNJ 8 3 5 4 -------- ---- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- AstraZeneca 5 ------------- --- --- --- --- ------------------------------------------------------------------------------------------------------------------------------- Amgen 4 2 -------- ---- --- --- =============================================================================================================================== [] Market leading position in sequencing [] Access to solid business with sustainable cash flow and margins [] Complements current business [] Consistent with prior investments in genetics and diagnostic business Sources: IMS MIDAS in PADDS, Diagnostic industry analyst reports, Company reports; Based on 2010 sales * Lucentis sold by Roche in US, by Novartis in RoW 21 < |
Transaction Financials: Summary [] In line with our stated M and A policy [] Solid business with sustainable cash flow and attractive margins [] Financial flexibility of Roche Group not significantly affected 22 |
Transaction Financials: Overview [] $44.50 per share in cash for each outstanding share of Illumina (fully diluted) [] Transaction valued at approximately $5.7 billion on a fully diluted basis [] Intend to promptly commence tender offer following repeated attempts to engage Offer Illumina management in discussions for a negotiated transaction [] Intend to promptly commence process to nominate slate of directors and make other proposals at Illumina's 2012 annual meeting which, if adopted, would result in Roche-nominated directors comprising a majority of Illumina's Board ---------- --- --------------------------------------------------------------------------------- [] 64% premium to $27.17, Illumina's unaffected close on Dec 21, 2011 Implied [] 61% premium to $27.65, Illumina's 1-month average trading price* Premium [] 43% premium to $31.02, Illumina's 3-month average trading price* ---------- --- --------------------------------------------------------------------------------- [] Tender by Illumina stockholders of number of shares, which, together with shares Offer owned by Roche, represents at least a majority of total number of shares outstanding on a fully diluted basis Conditions [] Roche's satisfaction that the anti-takeover provisions of the Delaware General Corporation Law are inapplicable to the proposed merger 23 * As of December 21, 2011, the day before market rumors about a potential transaction between Roche and Illumina drove Illumina's stock price significantly higher < |
Transaction Financials: Next steps [] Promptly commence tender offer to purchase all of the outstanding common stock of Illumina [] Offer will be subject to customary conditions [] Commence process to nominate slate of directors and make other proposals at Illumina's 2012 annual meeting which, if adopted, would result in Roche- nominated directors comprising a majority of Illumina's Board [] Commence regulatory process 24 |
Summary Deploying capital for the right strategic purposes [] Offer of $44.50 cash per share, representing an attractive value to Illumina's stockholders [] Sustainable cash flows and attractive margins [] Accretive to core EPS and operating profit in the first year post-closing [] Financial flexibility of the Roche Group not significantly affected Strengthens Roche's footprint in attractive and fast-growing sequencing market Enables Roche to access a solid business with positive cash flow and strong margins 25 |
We Innovate Healthcare 26 |